RIPK1 and inflammation: Inhibition of RIP1 signaling by necrostatin-1 has been shown to attenuate I/R injury [74], and phase 2 safety and efficacy trials in chronic inflammation have been undertaken of a small-molecule RIP1/RIP1K inhibitor, GSK2982772 [75] – but thus far, this inhibitor has not tested in the cardiovascular system.